Peer-influenced content. Sources you trust. No registration required. This is HCN.
OBR Oncology
The Supreme Court’s deliberations on the Chevron deference and FDA’s drug approval authority underscore a critical juncture for healthcare delivery and regulatory practices, potentially reshaping physician autonomy and patient care standards.
Hematology/Oncology April 1st 2024
MDLinx
Abdominal cancer is no longer an ailment confined to older demographics, with a notable uptick in cases among younger adults. Physicians are urged to consider early screening, especially for patients with familial cancer histories, amidst growing concerns over lifestyle and environmental influences.
Oncology, Medical April 1st 2024
The New England Journal of Medicine
The combination of ribociclib and a nonsteroidal aromatase inhibitor was associated with a notable improvement in invasive disease–free survival rates among early-stage, HR-positive, HER2-negative breast cancer patients, highlighting a significant advancement in the therapeutic landscape of this common malignancy.
Journal of Clinical Pathways
In the realm of oncology, AI’s potential to revolutionize patient care is immense, yet its successful integration hinges on stringent safety measures and a commitment to mitigating biases in data.
Hematology/Oncology March 25th 2024
In a significant stride toward personalized medicine, researchers have utilized AI to unveil two distinct evotypes of prostate cancer, heralding a new era in the disease’s diagnosis and management. This pivotal discovery opens doors to tailored treatment strategies, potentially mitigating the adverse effects of over-treatment in prostate cancer.
Explore the potential of CARv3-TEAM-E T cells in recurrent glioblastoma, a novel therapy showing promise with rapid tumor regression and no severe adverse effects in early clinical evaluation.
Oncology, Medical March 18th 2024